GABRIEL v. DSM BIOMEDICAL, INC.

CourtDistrict Court, E.D. Pennsylvania
DecidedAugust 6, 2025
Docket2:24-cv-04546
StatusUnknown

This text of GABRIEL v. DSM BIOMEDICAL, INC. (GABRIEL v. DSM BIOMEDICAL, INC.) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
GABRIEL v. DSM BIOMEDICAL, INC., (E.D. Pa. 2025).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

GERSEN GABRIEL : CIVIL ACTION : v. : : DSM BIOMEDICAL, INC. : NO. 24-4546

MEMORANDUM Savage, J. August 6, 2025 Gersen Gabriel, an African American, brought this employment discrimination action against his former employer, DSM Biomedical, Inc. (“DSM”). He claims DSM discriminated against him and subjected him to a hostile work environment based on his race, leading to his constructive termination. He alleges that DSM repeatedly audited and designated the manufacturing site under his management as an “issue site” as pretense to subject him to disciplinary action. He also claims DSM retaliated against him for filing an EEOC charge accusing DSM of racial discrimination when it placed him on paid suspension. Moving for summary judgment, DSM argues that Gabriel did not suffer an adverse action because his employment was unaffected by the audits and the issue site designation. It contends that Gabriel has not produced facts demonstrating intentional discrimination, and that the increased scrutiny at his worksite was justified by ongoing safety concerns. It adds that he was suspended in response to his erratic and threatening behavior. We conclude that Gabriel cannot establish a prima facie case of discrimination because there is no evidence that he suffered intentional discrimination or an adverse employment action. His retaliation claim fails because, like his discrimination claim, he did not suffer an adverse employment action. Background DSM, a nutrition, health, and beauty product manufacturer, operates 150 sites around the world.1 In 2020, DSM hired Gersen Gabriel as Senior Director of Global

Biomedical Operations.2 Gabriel was responsible for managing Site X and reported to John Witkowski, President of Biomedical Operations.3 DSM maintained a Safety, Health, and Environment (SHE) “Issue Site” list, which identified the ten sites most in need of safety improvements.4 Issue Sites were periodically monitored for progress in preventing workplace injuries.5 Issue Site designations were made after an analysis of “quantitative and qualitative” criteria, including: the total recordable injury rate compared to other sites; the number of recordable injuries; the seriousness of the incidents; and the safety, health, and environmental culture at the site.6

The SHE Department, led by Jeroen In de Braak, proposed which sites to add or remove from the Issue Site list.7 Philip Eykerman, President of the Health, Nutrition and

1 Def.’s Stmt of Material Undisputed Facts in Supp. of Mot. for Summ. J. ¶ 19, ECF No. 70-1 [“Def.’s SMF”]. 2 Id. ¶ 9; Pl.’s Resp. to Stmt of Facts; Pl.’s Counterstatement of Facts ¶ 9, ECF No. 89 [“Pl.’s SMF”]. 3 Def.’s SMF ¶¶ 9–11; Pl.’s SMF ¶¶ 9–11. We use a pseudonym to refer to Site X pursuant to the parties’ Stipulated Confidentiality Agreement. See Order, Feb. 5, 2025, ECF No. 28 (granting the parties’ Joint Motion for Entry of Stipulated Confidentiality Agreement); Order, May 7, 2025, ECF No. 86 (granting DSM’s motion to maintain the confidentiality of Site X’s location). 4 Def.’s SMF ¶ 19; Pl.’s SMF ¶ 19. Dep. of Philip Eykerman 14:8–12 (attached as Ex. 12 to Def.’s SMF), ECF No. 79 [“Eykerman Dep.”]. 5 Def.’s SMF ¶ 19; Pl.’s SMF ¶ 19. 6 Def.’s SMF ¶ 22; Pl.’s SMF ¶ 22. 7 Def.’s SMF ¶ 21; Pl.’s SMF ¶ 21; Eykerman Dep. 16:14–23, 18:10–16. Care Business, had the authority to accept or reject the recommendations.8 Eykerman testified that he has never disagreed with the SHE Department’s Issue Site recommendations.9 Site X was already on the Issue Site list when Gabriel was hired in 2020.10 Site X had two recordable injuries in 2020, 2022, and 2023, and one in 2021.11 DSM audited

Site X in 2021 and 2022.12 Citing the recordable injuries, DSM kept Site X on the Issue Site list in 2021, 2022, 2023, and 2024.13 In June 2022, Gabriel and In de Braak met for the first time in person. Gabriel testified that the interaction was “awkward,” and In de Braak had “looked at [him] weird” when he learned that Gabriel was the Director of Biomedical Operations.14 Gabriel felt that In de Braak was “surprised” that Gabriel was the supervisor instead of his white subordinate.15

8 Eykerman Dep. 10:19–14:7. 9 Id. at 13:4–14:7. 10 Def.’s SMF ¶ 25; Pl.’s SMF ¶ 25. 11 Feb. 2, 2021, Memo (attached as Ex. 14 to Def.’s SMF), ECF No. 76-6; Feb. 1, 2022, Memo (attached as Ex. 15 to Def.’s SMF), ECF No. 76-7; Feb. 6, 2023, Memo (attached as Ex. 16 to Def.’s SMF), ECF No. 76-8; May 2, 2024, Memo (attached as Ex. 17 to Def.’s SMF), ECF No. 76-9. 12 Def.’s SMF ¶¶ 42–43; Pl.’s SMF ¶¶ 42–43. DSM conducts two types of manufacturing site audits: Corporate Operational Audits (COAs) and Peer-to-Peer Audits (P2P audits). COA audits result in formal reports. They are not limited to SHE issues and assess all business functions. COA audits are typically conducted every three years. Def.’s SMF ¶¶ 39–40; Pl.’s SMF ¶¶ 39–40. P2P audits are limited to SHE issues. They are less formal than COA audits and do not result in an official report. P2P audits are typically conducted every 12–18 months. Def.’s SMF ¶ 41; Pl.’s SMF ¶ 41. 13 Def.’s SMF ¶¶ 26–29; Pl.’s SMF ¶¶ 26–29. 14 Dep. of Gersen Gabriel 46:16–49:22 (attached as Ex. 4 to Def.’s SMF), ECF No. 78 [“Gabriel Dep.”]. 15 Gabriel Dep. 364:7–22. In January 2023, Gabriel reported two injuries at Site X.16 In response, In de Braak expressed concern about continuing safety issues at Site X.17 DSM CEO Dimitri de Vreeze suggested an unannounced audit at Site X, which both Eykerman and In de Braak supported.18 The audit was conducted in June 2023.19 It found one high-risk and eleven medium-risk SHE issues.20

On January 25, 2024, Witkowski submitted an internal HR complaint based on reports of “unfair treatment” and “bias” against Gabriel and other African American employees by In de Braak and the SHE Department.21 As an example, Witkowski relayed Gabriel’s concern that In de Braak was unfairly targeting Site X.22 DSM conducted an internal investigation into the allegations against In de Braak. The investigation found “examples of micro-aggressions or un-conscious bias comments” by In de Braak, but “no confirmation of blatant racial discrimination.”23 The investigators recommended, among other things, mandatory unconscious bias retraining for In de Braak and the audit team, and the removal of Site X from the Issue Site list.24

On March 6, 2024, Witkowski resigned and accepted a new position at Solesis.25 A week later, Eykerman met with Gabriel to discuss the results of the internal

16 Jan. 20, 2023, Email from Gersen Gabriel (attached as Ex. 20 to Def.’s SMF), ECF No. 76-12. 17 Id. 18 Id. 19 July 11, 2023, Unannounced Audit Rep. (attached as Ex. 23 to Def.’s SMF), ECF No. 76-15. 20 Id. at 2. 21 Jan. 25, 2024, Email from John Witkowski (attached as Ex. 28 to Def.’s SMF), ECF No. [“Witkowski Compl.”]; see also Investigation File 2–3 (attached as Ex. 1 to Pl.’s SMF), ECF No. 90. 22 Investigation File 2. 23 Investigation Summary 4 (attached as Ex. 29 to Def.’s SMF), ECF No. 76-19. 24 Id. 25 Def.’s SMF ¶¶ 10, 57; Pl.’s SMF ¶¶ 10, 57. investigation.26 He offered Gabriel a $400,000 retention bonus to stay at DSM for at least three years.27 Gabriel declined the offer. By early April, 2024, Gabriel had decided that he “didn’t want to be part of [DSM].”28 On April 4, he texted Witkowski, “Can’t wait to join you!!”29 On April 29, he texted Witkowski, “Waiting for you to get me out!”30

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Belinda Hulsey v. Pride Restaurants
367 F.3d 1238 (Eleventh Circuit, 2004)
McDonnell Douglas Corp. v. Green
411 U.S. 792 (Supreme Court, 1973)
Texas Department of Community Affairs v. Burdine
450 U.S. 248 (Supreme Court, 1981)
Meritor Savings Bank, FSB v. Vinson
477 U.S. 57 (Supreme Court, 1986)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
St. Mary's Honor Center v. Hicks
509 U.S. 502 (Supreme Court, 1993)
Harris v. Forklift Systems, Inc.
510 U.S. 17 (Supreme Court, 1993)
Faragher v. City of Boca Raton
524 U.S. 775 (Supreme Court, 1998)
National Railroad Passenger Corporation v. Morgan
536 U.S. 101 (Supreme Court, 2002)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Bernadine Duffy v. Paper Magic Group, Inc
265 F.3d 163 (Third Circuit, 2001)

Cite This Page — Counsel Stack

Bluebook (online)
GABRIEL v. DSM BIOMEDICAL, INC., Counsel Stack Legal Research, https://law.counselstack.com/opinion/gabriel-v-dsm-biomedical-inc-paed-2025.